THE COMBINATION OF LOVASTATIN AND ENALAPRIL IN A MODEL OF PROGRESSIVE RENAL-DISEASE

被引：22

作者：

BROUHARD, BH

TAKAMORI, H

SATOH, S

INMAN, S

CRESSMAN, M

IRWIN, K

BERKLEY, V

STOWE, N

机构：

[1] Departments of Pediatrics, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio

[2] Departments of Hypertension/Nephrology, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio

[3] Departments of Cardiovascular Biology, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio

来源：

PEDIATRIC NEPHROLOGY | 1994年 / 8卷 / 04期

关键词：

ENALAPRIL; LOVASTATIN; PUROMYCIN; RENAL FAILURE; NEPHROTIC SYNDROME;

D O I：

10.1007/BF00856524

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Puromycin-induced nephrotic syndrome is an animal model of progressive renal disease. Both angiotensin converting enzyme inhibitors and lipid-lowering agents have been used to preserve renal structure and function in this model, although neither completely prevents progression. We tested the hypothesis that the combination of the two agents would be more protective than either alone. Rats were divided into five groups; all were uninephrectomized. Four groups were given puromycin at a dose of 10 mg/100 g body weight (BW) with additional doses of 4 mg/100 g BW given intraperitoneally at 4, 5, and 6 weeks thereafter. One group was given enalapril (EN) 50 mg/l dissolved in the drinking water; the second received lovastatin (L) 15 mg/kg given daily by gavage; the third received both agents; the fourth was left untreated, and the final group received no puromycin and served as the control group. Eight weeks after the initial dose of puromycin, glomerular filtration rate (GFR), as inulin clearance, and protein excretion were determined and blood was collected for cholesterol and triglycerides. Blood pressure was not different between any of the groups. At the end of the study period, serum cholesterol [mean +/- SD, 252 +/- 185 mg/dl (L), 135 +/- 101 mg/dl (L + EN)] and triglycerides (239 +/- 200, 148 +/- 158 mg/dl) were significantly lower (P < 0.001) in the lovastatin-treated groups than in the untreated puromycin group (535 +/- 255 mg/dl and 579 +/- 561 mg/dl, cholesterol and triglyceride, respectively). Likewise protein excretion was significantly lower (P < 0.001) in these groups also [507 +/- 336 (L), 253 +/- 331 (L + EN) vs. 745 +/- 381 (puromycin) mg/24 h]. Renal function was also preserved with a significantly better GFR per gram kidney weight in the lovastatin-treated groups [0.56 +/- 0.33 (L), 0.54 +/- 0.19 (L + EN) vs. 0.17 +/- 0.11 ml/min per gram]. Glomerulosclerosis, as measured by a sclerotic index, was also significantly less in the lovastatin plus enalapril-treated group (0.29 +/- 0.35) compared with the untreated puromycin group (2.29 +/- 0.54). Although enalapril had little effect by itself, the combination of enalapril and lovastatin appeared to significantly improve the decrease in serum cholesterol, triglyceride, and protein excretion. Thus treatment with lovastatin alone, and its subsequent lowering of serum cholesterol and triglyceride concentrations, improved renal structure and function in this model of puromycin nephrosis. The combination of lovastatin and enalapril resulted in the least histological damage, the least protein excretion, and preservation of GFR,

引用

页码：436 / 440

页数：5

共 23 条

[1]

Mitch W.E., Stein J.H., Contemp Issues Nephrol, 26, pp. 1-277, (1992)

[2]

Keane W.F., Anderson S., Aurell M., Angiotensin converting enzyme inhibitors and progressive renal insufficiency, ann Intern Med, 111, pp. 503-506, (1989)

[3]

Anderson S., Rennke H., Brenner B.M., Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat, J Clin Invest, 77, pp. 1993-1997, (1986)

[4]

Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M., Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J Clin Invest, 77, pp. 1925-1930, (1986)

[5]

Anderson S., Diamond J.R., Karnovsky M.J., Brenner B.M., Mechanisms underlying transition from active glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome, J Clin Invest, 82, pp. 1757-1768, (1988)

[6]

Kamper A.L., Strandgaard S., Leyssac P.P., Effect of enalapril on the progression of chronic renal failure, Am J Hypertens, 5, pp. 423-430, (1992)

[7]

Kasiske B.L., O'Donnell M.P., Schmitz P.G., Kin Y., Keane W.F., Renal injury of diet-induced hypercholesterolemia in rats, Kidney Int, 37, pp. 880-891, (1990)

[8]

Kasiske B.L., O'Donnell M.P., Cleary M.P., Keane W.F., Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats, Kidney Int, 3, pp. 667-672, (1988)

[9]

Harris K.P., Purkerson M.L., Yates J., Klahr S., Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome, Am J Kidney Dis, 15, pp. 15-23, (1990)

[10]

Fogo A., Yoshida Y., Glick A.D., Homma T., Ishkawa I., Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis, J Clin Invest, 82, pp. 322-330, (1988)

← 1 2 3 →